PharmaView   JAN.2007

Pharmaceutical Marketers are facing increasing pressures: increasing competition; squeezed margins; shrinking budgets; more to do and less time to do it. It’s becoming difficult to work any harder, and of course it's always better to work smarter. Therefore we bring you the PharmaView.

PharmaView is a biweekly educational and informative newsletter for improving readers’ marketing knowledge and reporting the latest news in the pharma industry. It also provides great opportunities to exchange ideas, network and be recognized among your peers in the industry.

Through PharmaView, you can:

Learn peer’s experience in pharma marketing

Stay in touch with what’s happening in pharmaceutical marketing today

Be on the pioneering edge of pharmaceutical marketing

Have networking / idea exchange opportunities

About Us 

Integrating local knowledge with international perspective, Consultech Co. Ltd. offers its clients and prospects one-lstop solutions with sales and marketing consultancy, advertising and promotion strategies.

Creative Design: Case study of Azmacort Visuals

                           

Eisai Announces Inovelon(R) Receives Marketing Authorization Approval from European Commission

Eisai Co., Ltd. announced today that on January 16 (U.K. time) the company's UK subsidiary Eisai Ltd. (Headquarters: London, Managing Director: Paul Hooper) received a marketing authorization approval for the anti-epileptic agent Inovelon(R) (rufinamide) indicated as adjunctive therapy in Lennox-Gastaut Syndrome (LGS) from the European Commission (EC).

Jan 22, 2007

Results Show XELOX (Xeloda(R) plus oxaliplatin) Provides Equivalent Overall Patient Survival Compared To FOLFOX In Advanced Colorectal Cancer

Overall survival results from an international, Phase III study (NO16966) suggest that XELOX (Xeloda(R) plus oxaliplatin) is an effective alternative to the current standard treatment, FOLFOX-4 (infused 5-FU/leucovorin plus oxaliplatin), for advanced (metastatic) colorectal cancer.

Jan 22, 2007

Wyeth depression/hot flash drug faces hurdles

Wyeth could win U.S. approval on Monday for a depression drug derived from the company's widely used Effexor XR, but its launch will be delayed by factory problems and issues with nausea, according to Wyeth and industry analysts.

Jan 22, 2007

Direct to Consumer: When Television Isn't Enough

It looks like 2006 will be remembered as the year the pharma sales-force arms race finally ended. But there are signs it might also be remembered as the year that direct-to-consumer advertising finally cooled off.

Jan 01, 2007

Marketing to Professionals: Tomorrow's Changes Today

How hard is it to spot an emerging threat or opportunity in time to actually do something about it? Is it as hard as spotting a scud missile in the deserts of Iraq? As hard as identifying an underwater threat to a submarine using only sonar? As hard as spotting a consumer trend in a vast and complex business like financial services?

Jan 01, 2007

Sales Management: Get Committed

Pharma companies today are focused on driving prescriptions. But just because physicians are prescribing a brand doesn't mean that they are committed to it. Who's to say a doctor won't jump ship the moment a flashier new drug comes on the scene?

Jan 01, 2007

Pfizer says considering OTC form of Viagra

Pfizer Inc. said on Wednesday it is considering an over-the-lcounter form of its Viagra anti-impotence drug as it faces tough competition from Eli Lilly and Co.'s longer-acting Cialis treatment.

Jan 11, 2007

WSJ examines Abbott AIDS drug pricing

Abbott tried to “diminish the attraction” of antiviral drug Norvir by raising its price, according to previously undisclosed documents and e-lmails reviewed by The Wall Street Journal.

Jan 09, 2007

Pfizer ups drug prices

Industry analysts say average wholesale prices for Pfizer drugs such as Lipitor and Celebrex went up by more than 5%, Reuters reported.

Jan 09, 2007

Lilly agrees to settle 18,000 more Zyprexa cases　

Eli Lilly agreed to pay up to $500 million to settle claims from about 18,000 patients who said the company hid the risks of weight gain and diabetes associated with Zyprexa.

Jan 09, 2007

Please feel free to offer your opinions and advices about PharmaView in order to better our services. Should you have any comments, or if you want to unsubscribe  from PharmaView, please send us an email: pharmaview@Consultech.com.cn  . Thank you!